在随机对照试验中,在多个时间点对代用终点的元分析评估,具有时间到事件终点
Xiaoyu Tang1, Ludovic Trinquart2,3,4
1Academy of Pharmacy, Xi'an Jiaotong-Liverpool University, Suzhou, China.
Clinical trials (London, England)
|October 16, 2025
概括
使用受限平均生存时间 (RMST) 差异的新元分析模型更有效地验证了代用终点. 这种方法可以解释时间滞后和随访持续时间的变化,从而改善了新疗法的评估.
科学领域:
- 生物统计学 生物统计学
- 临床试验方法论 临床试验方法论
- 药学指标 (Pharmacometrics) 是一个指标.
背景情况:
- 替代终点验证的传统元分析方法通常依赖于危险比率,并假定随着时间的推移治疗效果是恒定的.
- 现有的方法忽视了试验后续持续时间的变化以及代用和真实终点之间的关键时间滞后.
- 这些局限性阻碍了在时间到事件分析中使用替代终点对新疗法的准确评估.
研究的目的:
- 引入一种新的两阶段元分析模型,用于评估试验级别的代孕.
- 通过结合时间延迟和不同后续持续时间来解决现有方法的局限性.
- 为临床试验中替代终点验证提供更强大的框架.
主要方法:
- 拟议的模型使用第一阶段的受限平均存活时间 (RMST) 差异量化治疗效应.
- 第二阶段使用RMST的研究间共变矩阵来通过多个时间点的确定系数来评估代孕.
- 这个框架整合了没有外推的估计,明确模拟了终点时间滞后,并且在不成比例的危险下有效.
主要成果:
- 模拟研究表明,该模型提供了对确定系数的公正和精确估计.
- 应用到胃癌元分析表明,该模型捕捉了时间滞后和代孕强度的动态变化.
- 该模型的性能与克莱顿生存形模型 (Clayton survival copula model) 进行了有利的比较,这是一个标准参考方法.
结论:
- 使用RMST差异的新型元分析模型增强了替代终点验证的时间到事件结果.
- 它不需要比例危险假设,并随着时间的推移动态地捕捉了代孕力量.
- 该方法通过替代终点提高了通过替代终点评估新疗法的严谨性和实用性,特别是在存在时间滞后的情况下.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
551
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
551
01:18Introduction To Survival Analysis
745
Survival analysis is a statistical method used to study time-to-event data, where the "event" might represent outcomes like death, disease relapse, system failure, or recovery. A unique feature of survival data is censoring, which occurs when the event of interest has not been observed for some individuals during the study period. This requires specialized techniques to handle incomplete data effectively.
The primary goal of survival analysis is to estimate survival time—the time...
The primary goal of survival analysis is to estimate survival time—the time...
745
01:24Kaplan-Meier Approach
566
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
566
01:15Assumptions of Survival Analysis
391
Survival models analyze the time until one or more events occur, such as death in biological organisms or failure in mechanical systems. These models are widely used across fields like medicine, biology, engineering, and public health to study time-to-event phenomena. To ensure accurate results, survival analysis relies on key assumptions and careful study design.
391
01:09Censoring Survival Data
520
Survival analysis is a statistical method used to analyze time-to-event data, often employed in fields such as medicine, engineering, and social sciences. One of the key challenges in survival analysis is dealing with incomplete data, a phenomenon known as "censoring." Censoring occurs when the event of interest (such as death, relapse, or system failure) has not occurred for some individuals by the end of the study period or is otherwise unobservable, and it might have many different...
520
01:21Cancer Survival Analysis
645
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
645